Journal
NUTRIENTS
Volume 11, Issue 11, Pages -Publisher
MDPI
DOI: 10.3390/nu11112676
Keywords
immune response; gut microbiota; hypertension; endothelial dysfunction; nephritis
Categories
Funding
- Comision Interministerial de Ciencia y Tecnologia, Ministerio de Economia y competitividad (MINECO) [SAF2014-55523-R, SAF2017-84894-R]
- Junta de Andalucia [P12-CTS-2722, CTS 164]
- European Union
- Ministerio de Economia y Competitividad, Instituto de Salud Carlos III (CIBER-CV)
Ask authors/readers for more resources
The prevalence of renal and cardiovascular disease (CVD) in patients with systemic lupus erythematosus (SLE) is higher than in general populations. Recently, a causal role of gut microbiota on the development of immune responses in SLE has been described. Probiotic consumption changes the composition of gut microbiota, preventing SLE progression. The aim of this review is to explore the role of the gut microbiota in the development of renal and cardiovascular disease in SLE and how probiotics could be a therapeutic option. Despite strong evidence on the beneficial effects of probiotics in the development of autoimmunity and nephritis in SLE, only a few studies described the protective effects of Lactobacillus in important risk factors for CVD, such as endothelial dysfunction and hypertension in mice. The preventive effects of probiotics in renal and CVD in humans have not been established yet.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available